ReviewBMJ medicine2026
Eosinophilic oesophagitis: pathophysiology, diagnosis, and treatment.
Review in BMJ medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Relationship Between Eosinophilic Esophagitis and Laryngeal Manifestations: Pathophysiology, Clinical Overlap, and Diagnostic Challenges.Journal of clinical medicine · 2026Review
- The Potential Link Between Eosinophilic Esophagitis and Food Allergy: Inflammatory Pathogenesis and Management.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic oesophagitis is a chronic, immune mediated condition characterised by infiltration of eosinophils across the oesophageal mucosa and progressive oesophageal dysfunction. This specialist review explores the changes in understanding of eosinophilic oesophagitis across epidemiology, pathophysiology, diagnosis, and treatment. It highlights the interplay of genetic susceptibility, early life environmental exposures, and immune responses driven by type 2 helper T cells that underpin epithelial barrier dysfunction and fibrostenotic progression. Current diagnostic strategies rely on endoscopic biopsy, but emerging minimally invasive tests (including the oesophageal string test and transnasal endoscopy) offer promising alternatives for disease monitoring. Therapeutic approaches include dietary elimination, drug treatments (eg, proton pump inhibitors, topical corticosteroids), biologics (particularly dupilumab), and endoscopic dilation for fibrostenotic complications. Evidence from landmark trials and guidelines to support phenotype driven, patient centred management are also reviewed. As eosinophilic oesophagitis prevalence continues to rise globally, recent advances in targeted treatments and diagnostics are redefining long term care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.